The private sector holds great potential to reduce unmet need for family planning, and many countries are poised to adopt a total market approach for increasing contraceptive access through private pharmacies and drug shops. Policies supporting scale-up of family planning service provision and expanding method options such as DMPA-SC self-injection, must be prioritized in these entities.
The PATH-JSI DMPA-SC Access Collaborative and partners have gained valuable insights with relevance to private sector engagement on self-injection. This webinar held February 15, 2022 highlighted lessons learnt, challenges, recommendations, and considerations for policies supporting private sector engagement in self-injection in different country contexts. Specific topics included:
Financing and commodity production ecosystems
Procurement and supply chains
Service delivery and programming
Data reporting and monitoring
The discussion was moderated by Allen Namagembe, Deputy Project Director, Uganda DMPA-SC Access Collaborative, PATH.
Dr. Kayode Afolabi, Director and Head, Reproductive Health Division, Federal Ministry of Health, Nigeria
Dr. Daniella Munene, Member, National Executive Committee, Pharmaceutical Society of Kenya
Dr. Hortense Randrianaivo, President, Association of Pharmacists of Madagascar
Mr. Célestin Compaore, Regional Project Director, DMPA-SC, Jhpiego, Burkina Faso
This webinar hosted by the DMPA-SC Access Collaborative Learning and Action Networks (LAN) on July 21, 2021 highlighted important considerations for private pharmacies in data collection and reporting on self-care products such as DMPA-SC self-injection. Presenters shared their experiences and lessons from introducing DMPA-SC self-injection through private delivery channels in their respective countries.
The specific types of self-injection data collected across countries.
Best practices for engaging and motivating private sector pharmacies and drug shops to provide data to the public sector.
Tools used by pharmacies to collect self-injection data.
This virtual discussion encouraged all stakeholders—program implementers, researchers, government officials, health providers, and civil society members—to consider private sector perspectives on data collection and reporting practices, highlighting the importance of good private sector data to inform government policies and strategies for monitoring, regulating health products, and procurement.